Cantor Fitzgerald Forecasts Cytokinetics FY2025 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Cytokinetics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical company will earn ($4.75) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.23) per share.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $1.21 million. The company’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.35) earnings per share.

CYTK has been the topic of a number of other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a report on Monday, December 2nd. Royal Bank of Canada upped their target price on Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of Cytokinetics in a research report on Tuesday. Mizuho increased their target price on Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, Stifel Nicolaus assumed coverage on Cytokinetics in a report on Wednesday. They issued a “buy” rating and a $80.00 target price on the stock. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.40.

Cytokinetics Trading Up 2.2 %

NASDAQ:CYTK opened at $47.86 on Wednesday. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. Cytokinetics has a 1 year low of $44.49 and a 1 year high of $84.11. The stock has a market cap of $5.65 billion, a P/E ratio of -8.90 and a beta of 0.82. The stock has a 50-day simple moving average of $48.80 and a 200-day simple moving average of $53.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CYTK. R Squared Ltd acquired a new position in Cytokinetics in the fourth quarter worth approximately $133,000. Pacer Advisors Inc. lifted its position in shares of Cytokinetics by 2.9% in the fourth quarter. Pacer Advisors Inc. now owns 24,843 shares of the biopharmaceutical company’s stock worth $1,169,000 after purchasing an additional 690 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Cytokinetics by 85.8% during the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 842 shares in the last quarter. Inspire Investing LLC lifted its holdings in shares of Cytokinetics by 7.8% during the 4th quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 616 shares during the last quarter. Finally, Mirador Capital Partners LP increased its stake in shares of Cytokinetics by 1.6% during the 4th quarter. Mirador Capital Partners LP now owns 65,636 shares of the biopharmaceutical company’s stock worth $3,088,000 after purchasing an additional 1,010 shares during the last quarter.

Insider Transactions at Cytokinetics

In related news, Director Wendall Wierenga sold 4,452 shares of Cytokinetics stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $52.25, for a total transaction of $232,617.00. Following the sale, the director now directly owns 24,559 shares in the company, valued at $1,283,207.75. The trade was a 15.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Fady Ibraham Malik sold 2,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $45.92, for a total transaction of $91,840.00. Following the completion of the transaction, the executive vice president now owns 116,071 shares of the company’s stock, valued at $5,329,980.32. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,216 shares of company stock worth $2,799,276. 3.40% of the stock is currently owned by corporate insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.